Get the Stockscreener App
5.05
1.37%
-0.07
After Hours:
5.07
0.02
+0.40%
Curevac N V stock is traded at $5.05, with a volume of 644.42K.
It is down -1.37% in the last 24 hours and down -5.43% over the past month.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$5.12
Open:
$5.12
24h Volume:
644.42K
Relative Volume:
0.76
Market Cap:
$1.14B
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
9.2086
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
-1.37%
1M Performance:
-5.43%
6M Performance:
-9.82%
1Y Performance:
+57.81%
1-Day Range:
$5.05
$5.16
1-Week Range:
$5.05
$5.31
52-Week Range:
$2.475
$5.72
Curevac N V Stock (CVAC) Company Profile
Compare CVAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
5.05 | 1.15B | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Curevac N V Stock (CVAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-25-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-08-23 | Initiated | SVB Securities | Outperform |
| Jan-19-23 | Upgrade | UBS | Neutral → Buy |
| Jan-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Jun-17-21 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Underperform |
| Apr-26-21 | Initiated | Guggenheim | Neutral |
| Dec-10-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Sep-08-20 | Initiated | Credit Suisse | Neutral |
| Sep-08-20 | Initiated | Jefferies | Hold |
View All
Curevac N V Stock (CVAC) Latest News
CureVac Shareholders Approve BioNTech Exchange Offer - MSN
Trading Recap: Chien thuat ca cuoc dai han de kiem tienQuarterly Earnings Summary & Daily Growth Stock Tips - BỘ NỘI VỤ
Can CureVac N.V. stock reach $100 price targetWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - Newser
CureVac N.V. (CVAC): A Bull Case Theory - Finviz
Can CureVac N.V. stock sustain market leadershipGlobal Markets & Proven Capital Preservation Tips - Newser
BioNTech Satisfies Minimum Condition in CureVac Exchange Offer - TipRanks
BioNTech satisfies minimum condition in CureVac exchange offer - MSN
Biontech achieves minimum condition in CureVac exchange offer - marketscreener.com
BioNTech Achieves Minimum Condition in CureVac Exchange Offer - The Manila Times
BioNTech Announces Successful Tender of Over 81% of CureVac Shares, Subsequent Offering Period Now Open - Quiver Quantitative
BioNTech Achieves Minimum Condition in CureVac Exchange Offer - Benzinga
Movement Recap: Can MFSG stock resist broad market declinesQuarterly Performance Summary & Free Low Drawdown Momentum Trade Ideas - BỘ NỘI VỤ
Can New Board Leadership at CureVac (CVAC) Shift the Narrative After Recent Earnings Decline? - simplywall.st
CureVac NV Faces Valuation Shift Amid Declining Financial Performance Indicators - Markets Mojo
How CureVac N.V. stock reacts to Fed rate cutsEarnings Risk Report & Reliable Volume Spike Trade Alerts - moha.gov.vn
Carlson Capital L.P. Makes New Investment in CureVac N.V. $CVAC - MarketBeat
Transcript : CureVac N.V.Shareholder/Analyst Call - MarketScreener
CureVac (NASDAQ:CVAC) Sees Large Volume IncreaseHere's What Happened - MarketBeat
BioNTech Advances with CureVac Exchange Offer Approval - TipRanks
[6-K] BioNTech SE Current Report (Foreign Issuer) | BNTX SEC FilingForm 6-K - Stock Titan
CureVac Reports Q3 2025 Financial Results and Updates - MSN
BioNTech’s acquisition of CureVac nears completion as offer deadline approaches - Investing.com Nigeria
CureVac Form 6-K files EGM voting outcomes, joins BioNTech F-4 - Stock Titan
BioNTech (BNTX) Moves Forward with CureVac Acquisition - GuruFocus
BioNTech’s exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3 - Seeking Alpha
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration - The Manila Times
BioNTech Completes CureVac Share Exchange Offer Following Shareholder Approval - Quiver Quantitative
BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025 - TradingView — Track All Markets
BioNTech exchange offer for CureVac expires December 3 - StreetInsider
CureVac NV earnings beat by €0.08, revenue topped estimates - Investing.com South Africa
CureVac NV (FRA:5CV) PS Ratio : 14.01 (As of Nov. 25, 2025) - GuruFocus
EQS-News: CureVac Announces Voting Results of Extraordinary General Meeting - sharewise.com
CureVac (Nasdaq: CVAC) shareholders approve BioNTech exchange offer with 99.16% vote - Stock Titan
CureVac Announces Voting Results of Extraordinary General Meeting - The Derrick
How Investors May Respond To CureVac (CVAC) Reporting Sharp Decline in Quarterly Sales - Yahoo Finance
CureVac Beats Revenue Forecasts As BioNTech Takeover Advances - Finimize
CureVac (NASDAQ:CVAC) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
CureVac: Acquisition proceeding as planned; cash runway confirmed through 2028 - marketscreener.com
Company News for Nov 25, 2025 - sharewise.com
CureVac N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
MSN Money - MSN
CureVac Reports Q3 2025 Financials and BioNTech Transaction Progress - TipRanks
CVAC: Q3 2025 profit driven by one-time U.S. settlement, despite sharp revenue drop - TradingView
EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates - sharewise.com
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher - Benzinga
Curevac N V Stock (CVAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):